ArticleBioinformation2026
Clinical efficiency of mesenchymal stem cells for bone regeneration and osseointegration.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achieving predictable bone regeneration and optimal osseointegration remains a clinical challenge in dental implant therapy, particularly in sites with compromised bone quality. Therefore, it is of interest to evaluate the clinical efficiency of mesenchymal stem cells (MSCs) in enhancing bone regeneration and improving osseointegration in patients receiving dental implants. Hence, sixty patients were randomly divided into two groups: Group A received MSCs combined with bone grafts, while Group B received conventional bone grafts alone. Over a six-month follow-up period, Group A demonstrated significantly higher implant stability quotient (ISQ) values, greater bone volume gain and increased bone density compared to Group B. Implant survival was 100% in the MSC group, whereas the control group showed a survival rate of 96.7%. Thus, we show that the adjunctive use of mesenchymal stem cells can improve clinical outcomes in oral implantology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.